Welcome to our dedicated page for Arcus Biosciences SEC filings (Ticker: RCUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcus Biosciences, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company whose common stock trades on the New York Stock Exchange under RCUS. Form 8-K reports include quarterly and annual results furnished with pipeline updates, clinical program disclosures, collaboration updates, executive changes and material agreements tied to the company’s financing and development activities.
Arcus filings also cover capital structure and governance matters, including a completed common stock offering, amendments to a loan and security agreement, annual proxy materials, board and executive compensation disclosures, equity incentive matters and stockholder meeting proposals. The filing record reflects risk and operating disclosures connected to drug development, clinical studies, regulatory pathways, collaborations and funding needs.
Arcus Biosciences granted equity awards to its General Counsel, Carolyn C. Tang. She received 24,000 shares of common stock in the form of restricted stock units at a grant price of $0. These RSUs vest in four equal annual installments beginning on December 15, 2026, conditioned on her continued service with the company.
She was also granted a stock option for 96,000 shares of common stock with an exercise price of $22.13 per share. This option becomes exercisable in 48 equal monthly installments after January 1, 2026, also subject to continued service. Following these transactions, Tang directly beneficially owns 148,734 shares of common stock, which includes unvested RSUs, and holds 96,000 stock options.
Arcus Biosciences granted Chief Financial Officer Robert C. Goeltz II new equity awards. On 01/23/2026, he received 24,000 shares of common stock in the form of restricted stock units at a grant price of $0. These RSUs vest in four equal annual installments beginning on December 15, 2026, as long as he continues serving the company.
He was also granted a stock option to buy 96,000 shares of common stock at an exercise price of $22.13 per share. This option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to his continued service. Following the RSU grant, he beneficially owned 91,924 shares of common stock directly, which includes unvested RSUs.
Arcus Biosciences Chief Accounting Officer Alexander Azoy received new equity awards in the form of restricted stock units and stock options. On January 23, 2026, he was granted 21,050 shares of Common Stock as restricted stock units at a price of $0. These RSUs vest in four equal annual installments beginning on December 15, 2026, as long as he continues serving the company.
On the same date, he also received a stock option to buy 14,050 shares of Common Stock at an exercise price of $22.13 per share, with no cost for the grant itself. This option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to his continued service. After these transactions, he beneficially owned 39,581 shares of Common Stock, including unvested RSUs, held directly.
Arcus Biosciences Chief Operating Officer receives new equity awards. On January 23, 2026, COO Jennifer Jarrett was granted 31,000 shares of common stock in the form of restricted stock units, which vest in four equal annual installments beginning on December 15, 2026, as long as she continues serving the company. She also received a stock option covering 126,000 shares of common stock at an exercise price of $22.13 per share. This option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to her continued service. Following these grants, she directly holds 224,024 shares of common stock, including unvested RSUs, and 126,000 stock options.
Arcus Biosciences Chief Executive Officer and director Terry J. Rosen reported a charitable gift of company stock. On 01/08/2026, Rosen donated 35,000 shares of Arcus Biosciences, Inc. common stock, coded as a charitable gift transaction. The shares were transferred at a reported price of $0 per share, consistent with a non-cash donation. After this gift, Rosen beneficially owned 2,157,409 shares of common stock, which the disclosure notes includes the unvested portion of his restricted stock unit grants. This filing updates the market on Rosen’s current direct equity stake in the company.
BlackRock, Inc. reports beneficial ownership of 12,736,927 shares of Arcus Biosciences common stock, representing 10.4% of the outstanding class as of the event date. BlackRock has sole voting power over 12,575,912 shares and sole dispositive power over 12,736,927 shares, with no shared voting or dispositive power.
The filing states that various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Arcus Biosciences’ common shares. BlackRock certifies that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Arcus Biosciences president Juan C. Jaen reported indirect sales of Arcus Biosciences common stock held by a trust associated with him. On January 5, 2026, the trust sold 29,670 shares at a weighted average price of $21.34, 2,053 shares at a weighted average price of $22.34, and 100 shares at $23.20, under a Rule 10b5-1 trading plan adopted on August 8, 2025.
Following these transactions, the trust continued to hold 922,240 shares of Arcus Biosciences common stock. Jaen also reported 346,012 shares held directly, which include the unvested portion of his restricted stock unit grants.
A trust associated with RCUS stock filed a Rule 144 notice to sell 31,823 shares of Class A common stock through Goldman Sachs & Co. LLC on approximately 01/05/2026. The shares have an aggregate market value of $692,786.71, compared with 122,856,086 shares of this class reported as outstanding. The shares were originally acquired from the issuer in a private transaction on 05/08/2015 for full cash payment. The same trust has sold Class A common stock in prior months, including 44,950 shares on 11/17/2025 for gross proceeds of $913,028.90 and 50,000 shares on 12/04/2025 for $1,230,350.00.
Arcus Biosciences, Inc. Chief Financial Officer reported a sale of company stock in a routine insider transaction. On 12/31/2025, the reporting person sold 6,552 shares of Arcus Biosciences common stock at a price of $23.38 per share. After this transaction, the insider beneficially owned 67,924 shares of common stock in the company.
The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares according to a predetermined schedule, helping separate trading decisions from day-to-day nonpublic information about the business.
Arcus Biosciences, Inc. reported an insider share transfer by its Chief Executive Officer and director. On 12/30/2025, the reporting person transferred 2,400 shares of common stock at a reported price of $0, using transaction code G. After this transaction, the individual directly beneficially owns 2,192,409 shares of Arcus common stock.
According to the notes, the 2,400 shares were transferred to various family trusts in which the reporting person has no pecuniary interest, while retaining voting and dispositive power over all of the transferred shares.